Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences
- PMID: 30341895
- DOI: 10.1111/head.13407
Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences
Abstract
Objectives: To summarize the baseline methods for the Migraine in America Symptoms and Treatment (MAST) Study and evaluate gender differences in sociodemographics and headache features; consultation and diagnosis patterns; and patterns of acute and preventive treatment use for migraine among study participants.
Background: The MAST Study is a longitudinal, internet-based panel study of symptoms, approaches to management, and unmet treatment needs among US adults with migraine. This analysis focuses on the initial cross-sectional survey, conducted beginning in 2016, and is intended to update results from earlier national epidemiologic surveys of people with migraine in the United States.
Methods: Respondents to the MAST Study were recruited from a US nationwide online research panel. Stratified random sampling identified a representative cohort of adults (aged ≥18 years). We administered a validated diagnostic screener based on modified ICHD-3 beta criteria to identify individuals with migraine averaging at least 1 monthly headache day (MHD) over the previous 3 months. A baseline assessment evaluated sociodemographic and headache features, patterns of consultation and diagnosis, and use of acute and preventive medications for migraine. Frequency data and chi-square contrasts (P < .05) were used to compare respondents based on gender.
Results: Baseline survey data (N = 95,821) identified 18,353 respondents who met criteria for migraine, including 15,133 (women n = 11,049, men n = 4084) reporting at least 1 MHD for the preceding 3 months. The mean age of the sample was 43.1 (13.6) years; 73.0% of respondents were women, and 81.0% were Caucasian. Compared with men, women were younger (46.1 vs 42.0 years; P < .001); had more MHDs (5.6 vs 5.3; P < .001); and were more likely to report moderate or severe headache-related disability (45.9% vs 35.8%; P < .001) and cutaneous allodynia (43.7% vs 29.5%; P < .001). The lifetime rate of medical consultation for headache was 79.8% overall and slightly higher in women than in men. Women were more likely than men to have been diagnosed with migraine (48.3% vs 38.8%, P < .001). While 95.1% of people with migraine currently used acute treatment, the majority (58.9%) used over-the-counter (OTC) drugs to the exclusion of prescription drugs, while 11.3% used exclusively prescription drugs, and 20.5% used both. Among acute prescription medication users, women were more likely than men to take triptans (17.7% vs 14.3%, P < .001), while men were more likely than women to take opioids (14.5% vs 9.2%, P < .001). Oral formulations were used predominately (92.7% of the medication users), but men were more likely to use nasal sprays (13.6% vs 9.4%, P < .001) and injectables (7.9% vs 3.4%, P < .001). Men (14.5%) were also significantly more likely than women (10.4%) to be taking daily oral preventive medication (P < .001).
Conclusions: The MAST Study identified a large sample of women and men with migraine from a sampling frame that broadly resembles the US population. Low participation rate increases the risk of response bias, however, comparisons with Census data and prior population studies for the demographic and headache characteristics of the current sample suggest that findings are generalizable to the population of people with migraine. Women had more MHDs than men, and they were more likely to report migraine-related disability and cutaneous allodynia. The lifetime consultation rate for headache was relatively high, but many with migraine symptoms reported never having received a diagnosis of migraine from a healthcare professional. Acute prescription and preventive migraine treatments are underused. Migraine persists as an underdiagnosed and undertreated public health problem in 2018, and there are many opportunities to improve the diagnosis and treatment of people with this painful, disabling condition.
Keywords: allodynia; epidemiology; gender; migraine; treatment optimization; treatment patterns.
© 2018 American Headache Society.
Similar articles
-
Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.J Headache Pain. 2018 May 24;19(1):38. doi: 10.1186/s10194-018-0865-z. J Headache Pain. 2018. PMID: 29797100 Free PMC article.
-
Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study.Headache. 2020 Feb;60(2):416-429. doi: 10.1111/head.13708. Epub 2019 Dec 14. Headache. 2020. PMID: 31837007 Free PMC article.
-
Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study.Headache. 2019 Sep;59(8):1310-1323. doi: 10.1111/head.13588. Epub 2019 Aug 13. Headache. 2019. PMID: 31410844 Free PMC article.
-
Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study.J Headache Pain. 2023 Jul 17;24(1):88. doi: 10.1186/s10194-023-01623-z. J Headache Pain. 2023. PMID: 37460942 Free PMC article. Review.
-
The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies.Headache. 2013 Mar;53(3):427-36. doi: 10.1111/head.12074. Epub 2013 Mar 7. Headache. 2013. PMID: 23470015 Review.
Cited by
-
Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment Options.J Clin Med. 2024 May 8;13(10):2768. doi: 10.3390/jcm13102768. J Clin Med. 2024. PMID: 38792309 Free PMC article.
-
Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial.J Headache Pain. 2024 May 21;25(1):83. doi: 10.1186/s10194-024-01783-6. J Headache Pain. 2024. PMID: 38773375 Free PMC article. Clinical Trial.
-
Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.J Headache Pain. 2024 Apr 16;25(1):57. doi: 10.1186/s10194-024-01731-4. J Headache Pain. 2024. PMID: 38627638 Free PMC article. Clinical Trial.
-
The crucial role of locus coeruleus noradrenergic neurons in the interaction between acute sleep disturbance and headache.J Headache Pain. 2024 Mar 5;25(1):31. doi: 10.1186/s10194-024-01714-5. J Headache Pain. 2024. PMID: 38443795 Free PMC article.
-
Harris Poll Migraine Report Card: population-based examination of high-frequency headache/migraine and acute medication overuse.J Headache Pain. 2024 Feb 26;25(1):26. doi: 10.1186/s10194-024-01725-2. J Headache Pain. 2024. PMID: 38408888 Free PMC article.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous